Why These Analysts Cut Price Target On Teleflex

Loading...
Loading...
  • RBC Capital Markets says that Teleflex Incorporated TFX delivered a Q1 beat and maintained 2022 guidance. 
  • Despite that, the stock plunged as much as 11% in intra-day trading, driven by concerns around UroLift's growth trajectory implied in 2H FY22 and fx/ inflation headwinds to EPS. 
  • The analysts believe TFX's underlying business is tracking ahead of expectations, and they are comfortable at the mid-to-upper end of the 2022 revenue range. 
  • RBC has lowered the price target to $390 from $415 to reflect market multiples and maintain Outperform rating.
  • Teleflex reported Q1 revenues of $641.7 million, up 1.2% Y/Y (+3.2% on a constant currency basis), beating the consensus of $633.97 million.
  • Adjusted EPS of $2.88 beat the consensus of $2.75.
  • It reiterated GAAP and constant currency revenue growth of 2.3% - 3.8% and 4.0% - 5.5%, respectively, with adjusted EPS of $13.70 - $14.30.
  • Raymond James writes 1Q results were solid. UroLift beat the analyst consensus, but investors were likely looking for a bit more to help ease the steepness of the implied 2H ramp. Additionally, the FX guidance may have caused some angst. 
  • The analyst has changed the 2022 and 2023 estimates. Raymond James has lowered the price target from $380 to $355, with no change in Outperform rating.
  • Price Action: TFX shares are down 2.50% at $288.12 during the market session on the last check Friday.
Loading...
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: Analyst ColorEarningsNewsGuidanceHealth CarePrice TargetReiterationAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...